A Phase 2 interventional study of Cyclosporine A and Placebo in Dry Eye Syndromes, sponsored by Novaliq GmbH. Completed at 4 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-11-06.
Sponsored by Novaliq GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 3rd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 19th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
Novaliq GmbH is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
11 studies in Dry Eye Syndromes by Novaliq GmbH: none open now, none under way, none of them phase 3. Of 11 finished, 6 (55%) have results posted.
Among the 11 studies in Dry Eye Syndromes by Novaliq GmbH, this one is one of 2 that started in 2016, is one of 2 in phase 2, and was the 4th registered.
Novaliq GmbH’s Dry Eye Syndromes studies by the year they started, since 2013.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
Among Novaliq GmbH’s 11 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).
This phase 2 study explored the safety, efficacy and tolerability of two CyclASol concentrations as one drop twice daily versus vehicle (placebo). In addition to the masked vehicle control arm, an open-label comparator arm consisting of Restasis was included.
The study explored a range of signs and symptoms of DED to gain an understanding of the possible treatment effects in comparison to vehicle and estimation of effect sizes. In line with current treatment guidelines, the proposed phase 2 population consisted of patients suffering from moderate to severe DED.
The primary treatment comparisons in this study were between the two CyclASol concentrations versus vehicle for the sign variable total corneal fluorescein staining and the symptom variable dryness severity visual analogue scale at day 113. All other comparisons between treatments groups were considered secondary analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cyclosporine A solution (dose-level 1) in vehicle
Drug: Cyclosporine A
Cyclosporine A solution (dose-level 2) in vehicle
Drug: Cyclosporine A
Vehicle only
Drug: Placebo
Cyclosporine A 0.05% ophthalmic emulsion
Drug: Cyclosporine A
topical ocular, eye drops
Also known as: Ciclosporin, CsA
topical ocular, eye drops
Also known as: Excipient
Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days
The primary analysis and objective of the study was to compare the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. The sign endpoint was the change from baseline in total corneal fluorescein staining at day 113. The cornea is divided into five regions: central, superior, inferior, nasal and temporal. Each region is graded from 0-3 based on the National Eye Institute scale, where 0 indicates no staining and 3 maximal staining. The total score is the sum of all these regions. The maximum score for each eye is 15.
Time frame: Baseline to 113 Days
Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days
The primary analysis and objective of the study was to compare the the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. Furthermore, the open label character could have had an impact on patient reported outcomes. The symptom endpoint was the change from baseline in severity of dryness VAS at Day 113. Dryness severity was rated from 0 to 100%, where 0% corresponds to "no dryness" and 100% corresponds to "maximum dryness".
Time frame: Baseline to 113 Days
| Milestone | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution | Restasis |
|---|---|---|---|---|
| Started | 51 | 51 | 52 | 53 |
| Completed | 50 | 50 | 48 | 52 |
| Not completed | 1 | 1 | 4 | 1 |
The primary analysis and objective of the study was to compare the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. The sign endpoint was the change from baseline in total corneal fluorescein staining at day 113. The cornea is divided into five regions: central, superior, inferior, nasal and temporal. Each region is graded from 0-3 based on the National Eye Institute scale, where 0 indicates no staining and 3 maximal staining. The total score is the sum of all these regions. The maximum score for each eye is 15.
| units on a scale | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution |
|---|---|---|---|
| Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days | -2.38 ± 2.156 | -2.10 ± 2.252 | -1.69 ± 2.619 |
The primary analysis and objective of the study was to compare the the two CyclASol groups versus vehicle (all blinded treatment arms) for one sign and one symptom endpoint. The open label active comparator arm was not included in the primary analysis to reduce the number of comparisons. Furthermore, the open label character could have had an impact on patient reported outcomes. The symptom endpoint was the change from baseline in severity of dryness VAS at Day 113. Dryness severity was rated from 0 to 100%, where 0% corresponds to "no dryness" and 100% corresponds to "maximum dryness".
| units on a scale | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution |
|---|---|---|---|
| Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days | -11.00 ± 19.362 | -9.30 ± 27.832 | -13.85 ± 25.301 |
Collected over Adverse events reported were documented from the first dose of randomized study drug until the end of the last study day visit (day 113). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CyclASol 0.05% Ophthalmic Solution | 0/51 (0%) | 2/51 (3.9%) | 5/51 (9.8%) |
| CyclASol 0.1% Ophthalmic Solution | 0/51 (0%) | 0/51 (0%) | 4/51 (7.8%) |
| Placebo Ophthalmic Solution | 0/52 (0%) | 0/52 (0%) | 4/52 (7.7%) |
| Restasis | 0/53 (0%) | 1/53 (1.9%) | 4/53 (7.5%) |
| Event | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution | Restasis |
|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/51 | 0/51 | 0/52 | 0/53 |
| Myocardial infarctionCardiac disorders | 1/51 | 0/51 | 0/52 | 0/53 |
| Ovarian CystReproductive system and breast disorders | 0/51 | 0/51 | 0/52 | 1/53 |
| Event | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution | Restasis |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 2/51 | 4/51 | 1/52 | 4/53 |
| NasopharyngitisInfections and infestations | 3/51 | 0/51 | 3/52 | 0/53 |
The full analysis set included all randomized participants.
| Age, Continuous(years) | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution | Restasis | Total |
|---|---|---|---|---|---|
| Mean | 64.3 ± 10.72 | 61.1 ± 12.29 | 61.3 ± 10.45 | 62.8 ± 11.20 | 62.4 ± 11.36 |
| Sex: Female, Male(Participants) | CyclASol 0.05% Ophthalmic Solution | CyclASol 0.1% Ophthalmic Solution | Placebo Ophthalmic Solution | Restasis | Total |
|---|---|---|---|---|---|
| Female | 38 | 36 | 39 | 40 | 153 |
| Male | 13 | 15 | 13 | 13 | 54 |
Plan to share: No
The record gives a start of Jan 2016, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine
Novaliq GmbH